TOP2A (Phospho-Thr1343) Antibody
- Known as:
- TOP2A (Phospho-Thr1343) Antibody
- Catalog number:
- 11763
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Signalway
- Gene target:
- TOP2A (Phospho-Thr1343) Antibody
Related genes to: TOP2A (Phospho-Thr1343) Antibody
- Gene:
- TOP2A NIH gene
- Name:
- DNA topoisomerase II alpha
- Previous symbol:
- TOP2
- Synonyms:
- -
- Chromosome:
- 17q21.2
- Locus Type:
- gene with protein product
- Date approved:
- 1989-03-23
- Date modifiied:
- 2017-08-04
Related products to: TOP2A (Phospho-Thr1343) Antibody
Related articles to: TOP2A (Phospho-Thr1343) Antibody
- Preoperative differentiation between uterine mesenchymal tumors and benign uterine fibroids remains challenging in postmenopausal women. This study aimed to develop an exploratory risk-stratification model for uterine mesenchymal tumors and to characterize complementary molecular features of uterine leiomyosarcoma using a public transcriptomic dataset. A retrospective case-control study was conducted in postmenopausal patients with uterine masses who underwent surgery between 2011 and 2021. A total of 23 uterine mesenchymal tumor cases and 92 frequency-matched fibroid controls were included. Clinical variables were analyzed using univariable and multivariable logistic regression to develop an exploratory risk-stratification model. Model performance was evaluated using ROC analysis, calibration analysis, decision curve analysis, and confusion matrix assessment. Exploratory transcriptomic analysis was performed using the GEO dataset GSE64763 to characterize molecular differences between uterine leiomyosarcoma and fibroid tissues. Pelvic pressure, abnormal uterine bleeding, and tumor diameter were independently associated with uterine mesenchymal tumors. The model achieved an apparent AUC of 0.859 and an optimism-corrected AUC of 0.846 after 1000 bootstrap resamples. Exploratory transcriptomic analysis revealed distinct expression patterns and upregulation of proliferation-associated genes, including CCNB1, BUB1B, PRC1, TOP2A, and FOXM1, with enrichment of cell cycle-related pathways. An exploratory model based on routinely available preoperative variables demonstrated preliminary discriminatory ability within the development cohort. Independent external validation in representative prospective cohorts is required before any assessment of clinical utility. - Source: PubMed
Publication date: 2026/07/31
Wan XiaojieZhang TaoLi JingyiSong ZhiminRuan FeiLuo Jie - Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, with limited therapeutic efficacy due to tumor heterogeneity in conventional treatments. In the present study, an integrative, network pharmacology approach was employed to elucidate the multi-target mechanism of action of phytochemicals derived from Glossocardia bosvallia against NSCLC. Among 38 phytocompounds identified, 31 compounds that satisfied pharmacokinetic properties were selected for subsequent analysis. Ligand-based target prediction identified 429 potential protein targets, which are integrated with the top 250 differentially expressed genes obtained from the GSE33532 dataset. Intersection analysis identified eight therapeutic targets: PTGES, SRD5A1, CDK1, KIF11, TOP2A, CDC45, MB, and CHEK1. Protein-protein interaction and enrichment analyses demonstrated that these targets are predominantly involved in cell cycle regulation, mitotic cell cycle, and DNA replication pathways. Gene expression analysis demonstrated significant overexpression of the prioritized targets in NSCLC tissues, while survival analysis identified CHEK1 as the gene significantly associated with survival (p < 0.05). Molecular docking identified TOP2A_quinic acid as the most favorable complex, exhibiting a binding affinity of -12.27 kcal/mol, KIF11_linoleic acid as -12.10 kcal/mol and CHEK1_2,3-dihydro-3,5-dihydroxy-6-methyl-4h-pyran-4-one as -6.75 kcal/mol, which was further validated by dynamic simulations, principal component analysis based free energy landscape, and DSSP analysis, confirming the stability of the protein. This integrative framework provides a robust strategy for identifying biologically relevant and therapeutically actionable targets supporting the potential of G. bosvallia-derived phytochemicals as promising candidates for NSCLC. - Source: PubMed
Publication date: 2026/08/04
Kulandhaivel Soundar RajanStalin AntonyMuthuramalingam PandiyanSivaprakasam BalasubramanianJesudass Joseph Sahayarayan - Cervical cancer remains a major global health challenge, particularly in low-resource settings where treatment efficacy is limited by drug resistance and toxicity. Although (Sanqi) has demonstrated anticancer activity, its molecular mechanisms against cervical cancer remain insufficiently understood. - Source: PubMed
Publication date: 2026/07/10
Kamal ShahQin ChenWang YanjuanHe RuilinAmjad Kamal MohammadLi Wenji - Gliomas are characterized by poor survival rate and limited options for treatment. Based on the transcriptional enrichment for oligodendrocyte progenitor cell (OPC) transcripts, the proneural glioma is thought to arise from transformation of OPCs. Here, we injected mutant BB-p53n OPCs (with deletion and PDGF-BB overexpression) into recipient mice and performed single-nucleus RNA sequencing (snRNA-seq) of the injected cells and of brain tissue at early and late time points after injection, coincident with neuroimaging detection of tumoral masses. Analysis of tumor-bearing brain samples, identified a cluster that was not detected in the normal brain, but was enriched for OPC markers ( cell cycle genes () and glioma markers (), which we named "OPC-like." The clusters with "OPC-like" signature, were also the ones with greater genomic distribution of inferred copy number variations (inferCNVs) and high proliferative rate, and were therefore denoted as "tumors." The inferCNV genomic load was higher in late-stage samples compared to early ones, indicative of progressive genomic instability. Immunohistochemical analysis validated the high proliferative rate and widespread expression of the "OPC-like" markers TOP2A and SOX2. Pseudotime analysis of cycling cells identified a trajectory of decreasing cell cycle checkpoint regulation and increasing synaptic signaling from early to late timepoints. Thus, the early timepoints were characterized by the emergence of highly proliferative cell clusters with a unique "OPC-like" transcriptional signature and inferCNVs, and the late timepoints were characterized by further genomic spreading of inferCNVs, loss of cell cycle checkpoints and transcriptional changes consistent with increased neuron-glioma interactions. - Source: PubMed
Publication date: 2026/06/30
Huang DennisMela AngelikiPark Hye-JinCanoll PeterCasaccia Patrizia - Elevated topoisomerase IIA (TOP2A) expression is consistently linked to poor prognosis, driving cancer progression through its role in DNA unlinking. Although TOP2A is well-established in other cancers, its prognostic value in bladder cancer remains unclear. This study was conducted to assess the prognostic significance of TOP2A for patients with bladder cancer. - Source: PubMed
Publication date: 2026/07/20
Hendri Ahmad ZulfanRobert RobertFebriyanto ToniLiliana BelindaPratama Angga Dewa MegatikaOey Oliver